Literature DB >> 8307106

[3H]gabapentin may label a system-L-like neutral amino acid carrier in brain.

R J Thurlow1, J P Brown, N S Gee, D R Hill, G N Woodruff.   

Abstract

The ability of large neutral amino acids to interact with a site in mouse and pig brain labelled by [3H]gabapentin was examined. As previously described for rat tissue, [3H]gabapentin bound to synaptic plasma membranes prepared from mouse or pig cerebral cortex with high affinity (Kinetically derived KD = 14 and 17 nM for mouse and pig, respectively). Equilibrium binding in each species was inhibited by gabapentin and a range of large neutral amino acids. L-leucine (IC50 = 80 nM), L-isoleucine (IC50 = 72 nM), L-norleucine (IC50 = 40 nM) and L-methionine (IC50 = 50 nM) were the most potent of those tested. Binding was also inhibited by L-phenylalanine (IC50 = 380 nM), L-valine (IC50 = 310 nM) and the selective system-L substrate 2-amino-2-carboxy-bicycloheptane (IC50 = 420 nM) but not by the sodium-dependent System-A substrate methylaminoisobutyric acid. The presence of a submaximal concentration of leucine reduced [3H]gabapentin binding affinity but did not affect the maximum number of binding sites, suggesting a competitive interaction between leucine and the binding protein. The results suggest [3H]gabapentin may label a site in brain that resembles the large neutral amino acid transporter described in other tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8307106     DOI: 10.1016/0922-4106(93)90204-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

2.  The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.

Authors:  Y Wang; D F Welty
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 3.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 4.  [The alpha2delta subunit of the voltage-dependent calcium channel. A new pharmaceutical target for psychiatry and neurology].

Authors:  D Wedekind; B Bandelow
Journal:  Nervenarzt       Date:  2005-07       Impact factor: 1.214

5.  Comparison of the uptake of [3H]-gabapentin with the uptake of L-[3H]-leucine into rat brain synaptosomes.

Authors:  R J Thurlow; D R Hill; G N Woodruff
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

6.  Comparison of the autoradiographic binding distribution of [3H]-gabapentin with excitatory amino acid receptor and amino acid uptake site distributions in rat brain.

Authors:  R J Thurlow; D R Hill; G N Woodruff
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

7.  Effect of L-methionine on hot flashes in postmenopausal women: a randomized controlled trial.

Authors:  Thomas Guttuso; Michael P McDermott; Phillip Ng; Karl Kieburtz
Journal:  Menopause       Date:  2009 Sep-Oct       Impact factor: 2.953

8.  Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin.

Authors:  B Brawek; M Löffler; D J Dooley; A Weyerbrock; T J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-12       Impact factor: 3.000

9.  Effects of L-isoleucine and L-valine on hot flushes and serum homocysteine: a randomized controlled trial.

Authors:  Thomas Guttuso; Michael P McDermott; Haiyan Su; Karl Kieburtz
Journal:  Obstet Gynecol       Date:  2008-07       Impact factor: 7.661

Review 10.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.